Maxim Group analyst Michael Okunewitch maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares closed ...

Shares of Gilead Sciences ( GILD -1.77%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what to expect. Gilead Sciences beat analysts’ revenue expectations by 7. ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Gilead Sciences (GILD – Research Report) and ...

What Happened? Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.6% in the morning session after the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of Gilead Sciences Inc. advanced 7.46% to $103.31 Wednesday, on what proved to be an all-around poor trading session ...

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...

Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer. The results of the TROPiCS ...